Short history of L-Dopa;Breve historia de la L-Dopa

Neurologia

Volumn 17, Issue 4, 2002, Pages 214-217

  Garcia Ruiz P J ^a   Meseguer, E ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

History of Medicine; L Dopa; Parkinson's disease

Indexed keywords

ARSENIC; ATROPINE; BENSERAZIDE; CAMPHOR; CARBIDOPA; DOPAMINE; LEVODOPA; NORADRENALIN; PHENYLALANINE; RESERPINE; SCOPOLAMINE; SEROTONIN; TYROSINE;

CORPUS STRIATUM; DEGENERATIVE DISEASE; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG RESEARCH; DYSKINESIA; GASTROINTESTINAL SYMPTOM; HUMAN; NAUSEA; NEUROCHEMISTRY; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; REVIEW; VOMITING;

ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; HISTORY, 20TH CENTURY; HUMANS; LEVODOPA; PARKINSON DISEASE; RESERPINE;

EID: 0036526153     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Oppenheim H. Parálisis agitante. En: Oppenhein H, editor. Tratado de las Enfermedades Nerviosas (Traducción de la Tercera Edición Alemana). Barcelona: F Seix, 1901; p. 810-29.
2. Von Domarus A. Parálisis agitante. En: Von Domarus, editor. Medicina Interna (Traducción de la Tercera Edición Alemana). Barcelona: Manuel Marín, 1930; p. 679-81.
3. Barraquer Bordás L, Torre Parera A. Fisiopatologfa del sistema extrapiramidal. Med Clin 1944;2:381-98.
4. Hoehn M, Yahr M. Parkinsonism: Onset, progression and mortality. Neurology 1967;17:427-42.
5. Sneader W. Psychopharmacological agents. En: Sneader W, editor. Drug discovery: The evolution of modern medicine. Chichester: John Wiley, 1985; p. 175-91.
6. Brodie B, Olin J, Kuntzman R, Shore P. Possible interrelationship between release of brain norepineprine and serotonine by reserpine. Science 1957;125:1293.
7. Carlsson A, Rosengren E, Bertler A, Nilsson J. Effect of reserpine on the metabolism of catecholamines. En: Garattini C, Ghetti W, editores. Psychotropic drugs. New York: Elsevier, 1957; p. 363-6.
8. Carlsson A, Lindquist M, Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957;180:1200.
9. Bertler A, Rosengren E. Occurrence and distribution of dopamine in brain and other tissues. Experientia 1959;15:10-11.
10. Carlsson A, The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 1959;11:490-3.
11. Hornykiewicz O D. Physiologic, biochemical and pathological bacgrounds of levodopa and possibilities for the future. Neurology 1970;20:1-5.
12. Wooten. Neurochemistry. En: Koller W, editor. Handbook of Parkinson's Disease. New York: Marcel Dekker, 1992; p. 285-301.
13. Growdon JH, Melamed E. Effects of oral L-tyrosine administration of CSF tyrosine and HVA levels in patients with Parkinson's disease. Neurology 1980;30:396.
14. Cotzias G, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-9.
15. Mark M, Duvoisin RC. The history of the medical therapy of Parkinson's Disease. En: Koller W, Paulson G, editors. Therapy of Parkinson's disease. New York: Marcel Dekker, 1995; p. 1-20.
16. McGeer PL, Boulding JE, Gibson WC, Foulkes RG. Drug induced extrapyramidal reactions. Treatment with diphenhydramine hydrochloride and dihydroxyphenylalanine. JAMA 1961;177:665-70.
17. Barbeau A, Sourkes TL, Murphy GF. Les catécholamines dans la maladie de Parkinson. En: De Ajuriaguerra J Monoamines et Systéme Nerveux Central. Paris: Masson, 1962; p. 925-7.
18. Duvoisin RC, Yahr M, Coté LJ. Pyridoxine reversal of L-DOPA effect in Parkinson's disease. Trans Am Neurol Assoc 1969;94:81-4.
19. Yahr M, Duvoisin R, Schear M, Barrett R, Hoehn M. Treatment of parkinsonism with levodopa. Arch Neurol 1969;21:343-54.
20. Birkmayer W. Clinical effect of L-dopa plus RO 4-4602. En: Barbeau A, McDowell FH, editors. L-dopa and Parkinsonism. Philadelphia: FA Davis, 1970; p. 53-4.
21. Calne DB, Reid JL, Vakil SD, Rao S, Petrie A, Pallis CA, et al. Idiopathic parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa. BMJ 1971;3:729-32.
22. Symposium I. Therapeutic Controversies in Movement Disorders (Chairman: Stanley Fahn). Transactions of the American Neurological Association 1979, vol 14.
23. Rajput A H, Uitti R, Rajput A H, Offord K. Timely levodopa administration prolongs survival in Parkinson's disease. Parkinsonism Related Disorders 1997;3:159-65.